Clinical Trial

Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD

Study acronym: Ertu-NASH
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated March 21, 2025 (before its estimated November 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-11-30.
Status change: Not Yet Recruiting → Recruiting 2025-03-19
Trial Details
NCT Number NCT05644717
Lead Sponsor Getz Pharma
Conditions Liver Fat, Liver Fibrosis, Glycemic Control, Body Weight Changes, Waist Circumference, Tolerance
Enrollment 164 participants
Start Date 2023-03-01
Primary Completion 2025-11-01 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-21